The GALK2 Knockout Raji Polyclonal Cells are a CRISPR/Cas9-edited polyclonal population of Raji B lymphocytes with targeted disruption of the GALK2 gene. This polyclonal knockout format provides a heterogeneous cell pool that retains the inherent cellular diversity of the Raji line while ensuring robust loss of GALK2 function. By employing CRISPR/Cas9-mediated gene disruption, the product establishes a stable loss-of-function model suitable for investigating galactose metabolism and glycan biosynthesis without the constraints of clonal selection. The cells offer a flexible platform for functional studies, enabling researchers to interrogate the metabolic and signaling consequences of GALK2 ablation in a human B-cell context.
The Raji cell line originates from a human Burkitt’s lymphoma, a B lymphocyte malignancy characterized by MYC translocation and aggressive proliferation. Widely used in immunology and cancer research, this suspension cell line exhibits rapid growth and is genetically tractable, facilitating efficient CRISPR editing and downstream assays. The B-cell origin of Raji cells makes them particularly relevant for exploring the role of sugar metabolism in immune cell function and tumorigenesis. Endogenous GALK2 expression in these cells provides a native genomic context for studying the effects of gene disruption on galactose-dependent pathways and glycosylation machinery.
GALK2 encodes galactokinase 2, an enzyme that catalyzes the ATP-dependent phosphorylation of galactose to galactose-1-phosphate, the initial step of the Leloir pathway. This reaction is essential for funneling galactose into glycolysis and glycoconjugate biosynthesis, and GALK2 also phosphorylates N-acetylgalactosamine, linking it to mucin-type O-glycosylation. The enzyme interacts with key Leloir components including GALT, GALE, and UGP2, and its activity is regulated by upstream substrates such as galactose and glucose. Downstream, galactose-1-phosphate serves as a precursor for UDP-galactose, a critical donor for glycosylation of proteins and lipids.
Disruption of GALK2 impairs this phosphorylation step, leading to galactose accumulation and deficits in glycolipid and glycoprotein production, with downstream effects on cellular energy metabolism and surface receptor glycosylation. In the Raji B-cell background, GALK2 knockout provides a physiologically relevant model to dissect the intersection of carbohydrate metabolism and cancer biology. Burkitt’s lymphoma cells rely on altered metabolic networks to sustain rapid proliferation; perturbing galactose utilization may uncover metabolic vulnerabilities or alter glycosylation of receptors involved in growth signaling and immune evasion. This knockout line allows researchers to explore how Leloir pathway dysfunction affects glycoconjugate synthesis, potentially influencing B-cell receptor signaling, apoptosis, and tumor progression.
Moreover, it serves as a human cell-based system to model metabolic disorders such as galactosemia and cataract, where GALK2 deficiency disrupts galactose homeostasis, and to test therapies aimed at restoring metabolic balance. Typical research applications encompass galactose consumption and metabolic flux assays to quantify pathway activity, Western blot and RT-qPCR for confirming target gene disruption and assessing expression of interacting proteins like GALT and UGP2, and galactose-1-phosphate measurement to validate enzymatic blockade. Investigators can profile glycosylation changes via lectin blots or mass spectrometry, and evaluate impacts on proliferation, apoptosis, and drug sensitivity in the lymphoma context. The polyclonal nature of these cells is ideal for screening experiments, long-term adaptation studies, and generating variant subpopulations for further analysis. For additional technical specifications and ordering details, please contact Ascent Research.
